114 related articles for article (PubMed ID: 7691393)
1. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer.
D'Amico AV; Hanks GE
Cancer; 1993 Nov; 72(9):2638-43. PubMed ID: 7691393
[TBL] [Abstract][Full Text] [Related]
2. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer.
Pollack A; Zagars GK; Kavadi VS
Cancer; 1994 Jul; 74(2):670-8. PubMed ID: 7518341
[TBL] [Abstract][Full Text] [Related]
3. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
D'Amico AV; Moul JW; Carroll PR; Sun L; Lubeck D; Chen MH
J Natl Cancer Inst; 2003 Sep; 95(18):1376-83. PubMed ID: 13130113
[TBL] [Abstract][Full Text] [Related]
4. Correlation of initial PSA level and biopsy features with PSA-doubling time in early stage prostate cancers in Japanese men.
Kakehi Y; Kamoto T; Shiraishi T; Kato T; Tobisu K; Akakura K; Egawa S; Maeda O; Sumiyoshi Y; Arai Y; Ogawa O
Eur Urol; 2002 Jan; 41(1):47-53. PubMed ID: 11999465
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
6. [PSA doubling time in prostate cancer relapsed after endocrine therapy].
Nakata S; Takahashi H; Takezawa Y; Kobayashi M; Matumoto K; Kosaku N; Kawashima K
Nihon Hinyokika Gakkai Zasshi; 2000; 91(7-8):584-8. PubMed ID: 10965743
[TBL] [Abstract][Full Text] [Related]
7. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer.
Zelefsky MJ; Ben-Porat L; Scher HI; Chan HM; Fearn PA; Fuks ZY; Leibel SA; Venkatraman ES
J Clin Oncol; 2005 Feb; 23(4):826-31. PubMed ID: 15681527
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy.
Zagars GK; von Eschenbach AC
Cancer; 1993 Jul; 72(2):538-48. PubMed ID: 7686443
[TBL] [Abstract][Full Text] [Related]
9. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
10. Determining if pretreatment PSA doubling time predicts PSA trajectories after radiation therapy for localized prostate cancer.
Soto DE; Andridge RR; Pan CC; Williams SG; Taylor JM; Sandler HM
Radiother Oncol; 2009 Mar; 90(3):389-94. PubMed ID: 18977051
[TBL] [Abstract][Full Text] [Related]
11. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH
J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735
[TBL] [Abstract][Full Text] [Related]
12. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume.
Schmid HP; McNeal JE; Stamey TA
Cancer; 1993 Mar; 71(6):2031-40. PubMed ID: 7680277
[TBL] [Abstract][Full Text] [Related]
13. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
14. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer.
D'Amico AV; Cote K; Loffredo M; Renshaw AA; Schultz D
J Clin Oncol; 2002 Dec; 20(23):4567-73. PubMed ID: 12454114
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen doubling times are similar in patients with recurrence after radical prostatectomy or radiotherapy: a novel analysis.
Leibman BD; Dillioglugil O; Scardino PT; Abbas F; Rogers E; Wolfinger RD; Kattan MW
J Clin Oncol; 1998 Jun; 16(6):2267-71. PubMed ID: 9626230
[TBL] [Abstract][Full Text] [Related]
16. The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer.
Zagars GK; Pollack A
Cancer; 1993 Aug; 72(3):832-42. PubMed ID: 7687516
[TBL] [Abstract][Full Text] [Related]
17. [Prostate specific antigen doubling time in prostate cancer before treatment and in refractory status].
Nakata S; Takezawa Y; Kobayashi M; Kuribara H; Matumoto K; Kosaku N; Suzuki T; Yamanaka H
Nihon Rinsho; 1998 Aug; 56(8):2026-30. PubMed ID: 9750501
[TBL] [Abstract][Full Text] [Related]
18. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.
Tollefson MK; Slezak JM; Leibovich BC; Zincke H; Blute ML
Mayo Clin Proc; 2007 Apr; 82(4):422-7. PubMed ID: 17418069
[TBL] [Abstract][Full Text] [Related]
19. Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer.
Rodrigues NA; Chen MH; Catalona WJ; Roehl KA; Richie JP; D'Amico AV
Cancer; 2006 Aug; 107(3):514-20. PubMed ID: 16795068
[TBL] [Abstract][Full Text] [Related]
20. Outcome of patients with hormone-refractory prostate cancer: prognostic significance of prostate-specific antigen-doubling time and nadir prostate-specific antigen.
Tomioka S; Shimbo M; Amiya Y; Nakatsu H; Murakami S; Shimazaki J
Jpn J Clin Oncol; 2008 Jan; 38(1):36-42. PubMed ID: 18258713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
